Rapport_Logo_Color_RGB.png
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
August 08, 2024 07:00 ET | Rapport Therapeutics, Inc.
Rapport Therapeutics announces financial results for Q2 2024 and provides a business update, including progress on its precision neuroscience pipeline
Jeanne Schow, Senior Vice President, Business Development
Avance Clinical Announces Senior Appointment to North American Operations
July 31, 2024 02:45 ET | Avance Clinical
ADELAIDE, Australia and WAKE FOREST, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, an award-winning, mid-sized full-service global Contract Research Organization (CRO) for biotech...
Kaerus Logo
Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
July 25, 2024 05:00 ET | Kaerus Bioscience
LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of...
logo-01 (3) copy - Copy2.jpg
ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome
July 24, 2024 10:00 ET | ConSynance Therapeutics
FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.
Rapport_Logo_Color_RGB.png
Rapport Therapeutics Announces Pricing of Initial Public Offering
June 06, 2024 18:54 ET | Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
Stalilcla logo.png
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder
May 02, 2024 08:01 ET | STALICLA
Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the...
YPrime CNS Survey - Key eCOA Attributes
New YPrime Report Highlights eCOA's Impact on CNS Trials
May 01, 2024 08:00 ET | Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.
alumis logo.png
Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005
April 30, 2024 08:00 ET | Alumis Inc
Alumis Inc. today announced that dosing has commenced in a Phase 1 clinical trial of A-005 in healthy participants.
fundamental pharma.png
FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer
April 11, 2024 07:00 ET | Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer Highly experienced biotech executive, with over a quarter of a century of CNS drug discovery experienceDr. Beher...
alumis logo.png
Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS
March 01, 2024 08:00 ET | Alumis Inc
– A-005 is a potential first-in-class, brain penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – – Data support planned Phase 1 clinical trial on track to...